On the stock market since 2007, it operates in the world of health and science. It has 373 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 39% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades 24% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 45% a year on average.
Sales run at $272.3M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 13 buys and 11 sells. Management buying with its own money is usually read as a good sign.
A loss of $5.1M against $272.3M in annual sales.
On our five-subject report card, HROW sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: HROW is a high-risk stock — not yet profitable, and its future rides on its product catching on.